Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 153-167 , November 2009

Dose–volume effects for normal tissues in external radiotherapy: Pelvis

  • Claudio Fiorino

      Affiliations

    • Medical Physics Department, San Raffaele Scientific Institute, Milan, Italy
    • Corresponding Author InformationCorresponding author. Address: Servizio di Fisica Sanitaria, Istituto Scientifico Ospedale San Raffaele, Via Olgettina 60, 20132 Milano, Italy.
    • ,
  • Riccardo Valdagni

      Affiliations

    • Prostate program, Scientific Directorate Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy
    • ,
  • Tiziana Rancati

      Affiliations

    • Prostate program, Scientific Directorate Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy
    • ,
  • Giuseppe Sanguineti

      Affiliations

    • Radiotherapy Department, The John Hopkins University, Baltimore, MD, USA

Received 23 February 2009 ,Revised 11 August 2009 ,Accepted 11 August 2009.

References 

  1. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  2. Jackson A. Partial irradiation of the rectum. Semin Radiat Oncol. 2001;11:215–223
  3. O’Brien PC. Radiation injury of the rectum. Radiother Oncol. 2001;60:1–14
  4. Van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to penile structures: a critical review. Radiother Oncol. 2007;84:107–113
  5. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know?. Crit Rev Oncol Hematol. 2006;57:165–173
  6. Jackson A, Skwarchuk M, Zelefsky M, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose–volume histograms. Int J Radiat Oncol Biol Phys. 2001;49:685–698
  7. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64:1–12
  8. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose–volume constraints in high-dose conformal radiotherapy for localized prostate cancer. J Radiat Oncol Biol Phys. 2003;57:953–962
  9. Rancati T, Fiorino C, Gagliardi G, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73:21–32
  10. Vargas C, Martinez A, Kestin LL, et al. Dose–volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1297–1308
  11. Peeters STH, Hoogeman M, Heemsbergen WD, et al. Rectal bleeding, fecal incontinence and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66:11–19
  12. Söhn M, Yan D, Liang J, et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose–volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 2007;26:1066–1073
  13. Tucker SL, Dong L, Bosch WR, et al. Fit of a generalized Lyman Normal tissue complication probability (NTCP) model to grade ⩾ 2 late rectal toxicity data from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys. 2007;69:S8–S9
  14. Rancati T, Fiorino C, Valvassori V, et al. Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modeling. Radiother Oncol. 2008;88:S332–S333
  15. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3DCRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130–1137
  16. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  17. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129
  18. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  19. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semim Radiat Oncol. 2008;18:48–57
  20. Hartford AC, Niemierko A, Adams JA, et al. Conformal irradiation of the prostate: estimating long term rectal bleeding risk using dose–volume histograms. Int J Radiat Oncol Biol Phys. 1996;36:721–730
  21. Boersma LJ, van den Brink M, Allison M, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78Gy) conformal radiotherapy for prostate cancer, using dose–volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  22. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  23. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dose–volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:1009–1019
  24. Zapatero A, Garcia-Vicente F, Modolell I, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose–volume effect. Int J Radiat Oncol Biol Phys. 2004;59:1343–1351
  25. Fenwick JD, Khoo VS, Nahum AE, et al. Correlations between dose–surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer, using dose–volume histograms. Int J Radiat Oncol Biol Phys. 2001;49:473–480
  26. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DVH and late rectal bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2Gy). Int J Radiat Oncol Biol Phys. 2003;55:688–694
  27. Wachter S, Gerstner N, Goldner G, et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose–volume histograms as predictive factors. Radiother Oncol. 2001;59:65–70
  28. Koper PCM, Heemsbergen WD, Hoogeman MS, et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1072–1082
  29. Greco C, Mazzetta C, Cattani F, et al. Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol. 2003;69:215–222
  30. Kupelian PA, Reddy CA, Klein EA, et al. Short-course intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys. 2001;51:988–993
  31. Van der Laan HP, van der Bergh A, Schilstra C, et al. Grading-system-dependent volume effects of late radiation induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1138–1145
  32. Fiorino C, Vavassori V, Sanguineti G, et al. Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose–volume histograms and normal tissue complication probability. Radiother Oncol. 2002;63:249–255
  33. Foppiano F, Fiorino C, Frezza G, et al. The impact of contouring uncertainty on rectal 3D dose–volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys. 2003;57:573–579
  34. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose response. Int J Radiat Oncol Biol Phys. 2000;47:103–113
  35. Heemsbergen WD, Hoogeman MS, Hart GA, et al. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1011–1018
  36. Peeters STH, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151–1161
  37. Munbodh R, Jackson A, Bauer J, et al. Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity-modulated radiation therapy for prostate cancer. Med Phys. 2008;35:2137–2150
  38. van Lin ENJT, Kristinsson J, Philippens MEP, et al. Reduced late rectal mucosal changes after three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys. 2007;67:78–83
  39. Goldner G, Tomicek B, Becker G, et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna rectoscopy score and correlated with EORTC/RTOG score for late rectal toxicity. Int J Radiat Oncol Biol Phys. 2007;67:78–83
  40. Pickett B, Vigneault E, Kurhanewicz J, et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90Gy compared to seven field three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44:921–929
  41. De Meerleer , et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75:325–333
  42. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  43. Koom W, Sohn D, Kyung K, et al. Computed tomography-based high-dose-rate intracavitary brachytherapy for uterine cervical cancer: preliminary demonstration of correlation between dose–volume parameters and rectal mucosal changes observed by flexible sigmoidoscopy. Int J Radiat Oncol Biol Phys. 2007;68:1446–1454
  44. Crosland A, Jones R. Rectal bleeding: prevalence and consultation behaviour. BMJ. 1995;311:486–488
  45. Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. Am J Gastroenterol. 1998;93:2179–2183
  46. Kang JY, Rink E, Sundaram KK, Hartley I. Factors associated with the frequency of stool examination: effect on incidence of reported rectal bleeding. Eur J Gastroenterol Hepatol. 2003;15:531–533
  47. Fonteyne V, De Neve W, Geert V, et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol. 2007;84:156–163
  48. Smit WG, Pa Helle , van Putten WL, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23–29
  49. Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 2002;86:1843–1847
  50. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:397–405
  51. Lawton CA, Bae K, Pilepich M, et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys. 2008;70:437–441
  52. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  53. Schultheiss TE, Hanks GE, Hunt MA, et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys. 1995;32:643–649
  54. Sanguineti G, Marcenaro M, Franzone P, et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol. 2003;66:151–157
  55. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997;49:38–45
  56. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460–2468
  57. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor of late radiation morbidity. Int J Radiat Oncol Biol Phys. 1999;43:475–479
  58. Moore , et al. Rectal bleeding after radiation therapy for prostate cancer: endoscopic evaluation. Radiology. 2000;217:215–218
  59. Vordemark D, Schwab M, Ness-Duurdoumas R, et al. Association of anorectal dose–volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiother Oncol. 2003;69:209–214
  60. Al Abany M, Helgason AR, Agren Cronqvist AK, et al. Dose to the anal-sphincter region and risk of fecal leakage. Acta Oncol. 2004;43:117–118
  61. Fellin G, Fiorino C, Rancati T, et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multi-center observational study. Radiother Oncol 2009; in press.
  62. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;60:77–84
  63. Karlsdottir A, Muren LP, Wentzel-Larsen T, et al. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys. 2008;70:1478–1486
  64. Michalsky JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004;58:735–742
  65. Sohn M, Alber M, Yan D. Principal component analysis-based pattern analysis of dose–volume histograms and influence on rectal toxicity. Int J Radiat Oncol Biol Phys. 2007;69:230–239
  66. Wang CJ, Leung SW, Chen HC, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys. 1998;40:85–91
  67. Heemsbergen WD, Peeters ST, Koper PC, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006;66:3–10
  68. Nuyttens JJ, Milito S, Rust PF, Turrisi AT. Dose–volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol. 2002;64:209–214
  69. Karlsdóttir A, Johannessen DC, Muren LP, et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol. 2004;71:43–53
  70. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63:1142–1152
  71. Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007;67:1401–1410
  72. Cheng JC, Schultheiss TE, Nguyen KH, Wong JY. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:351–357
  73. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3DCRT. Int J Radiat Oncol Biol Phys. 2008;71:1065–1073
  74. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  75. Lindsay PE, Moiseenko VV, Van Dyk J, et al. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Phys Med Biol. 2003;48:507–522
  76. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  77. Valdagni R, Italia C, Montanaro P, et al. Is the alpha–beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol. 2005;75:74–82
  78. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  79. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44:265–276
  80. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  81. Arcangeli S, Strigari L, Soete G, et al. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys. 2009;73:39–45
  82. Strigari L, Arcangeli G, Arcangeli S, Benassi M. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:1454–1460
  83. Lyman JT. Complication probability as assessed from dose–volume histograms. Radiat Res. 1985;104:S13–S19
  84. Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21:137–146
  85. Fellin G, Fiorino C, Rancati T, et al. Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modeling. Int J Radiat Oncol Biol Phys. 2008;72:S332;[Abstract]
  86. Mavroidis P, Al-Abany M, Helgason AR, et al. Dose–response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol. 2005;181:293–306
  87. Kallman P, Agren A, Brahme A. Tumor and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:249–262
  88. Li S, Boyer A, Lu Y, Chen GTY. Analysis of the dose–surface histogram and dose–wall histogram for the rectum and bladder. Med Phys. 1997;24:1107–1116
  89. MacKay RI, Hendry JH, Moore CJ, et al. Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose–surface histograms. Br J Radiol. 1997;70:517–526
  90. Meijer GJ, van der Brink M, Hoogeman MS, Meinders J, Lebesque JV. Dose–wall histograms and normalized dose–surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45:1073–1080
  91. Wachter S, Gerstner N, Dorner D, et al. The influence of a rectal ballon tube as internal immobilization device on variations of volumes and dose–volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:91–100
  92. Yan D, Xu B, Lockman D, et al. The influence of interpatient and intrapatient rectum variation on external beam treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:1111–1119
  93. Lebesque JV, Allison D, Bruce AM, et al. Variation in volumes, dose–volume histograms and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys. 1995;33:1109–1119
  94. Lu Y, Spelbring D, Song PY, et al. Dose–surface histograms as treatment planning tool for prostate conformal therapy. Med Phys. 1995;22:279–284
  95. Fiorino C, Gianolini S, Nahum AE. A cylindrical model of the rectum: comparing dose–volume, dose–surface and dose–wall histograms in the radiotherapy of prostate cancer. Phys Med Biol. 2003;48:2603–2616
  96. Garcia-Vicente F, Zapatero A, Floriano A, et al. Statistical analysis of dose–volume and dose–wall histograms for rectal toxicity following 3DCRT in prostate cancer. Med Phys. 2005;32:2503–2509
  97. De Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:965–973
  98. Heemsbergen WD, Hoogeman MS, Witte MG, et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68Gy versus 78Gy. Int J Radiat Oncol Biol Phys. 2007;67:1418–1424
  99. Stasi M, Munoz F, Fiorino C, et al. Emptying the rectum before treatment delivery limits the variations of rectal dose–volume parameters during 3DCRT of prostate cancer. Radiother Oncol. 2006;80:363–370
  100. Nijkamp J, Pos FJ, Nuver TT, et al. Adaptive radiotherapy for prostate cancer using kilovoltage con-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys. 2008;70:75–82
  101. Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, et al. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys. 2008;71:611–617
  102. Rancati T, Foppiano F, Pasquino M, et al. Impact of uncertainties on rectal NTCP modeling: fitting clinical data with the Lyman model. Radiother Oncol. 2005;73:S54–S55
  103. Rasch C, Remeijer P, Koper PCM, et al. Comparison of prostate cancer treatment in two Institutions: a quality control study. Int J Radiat Oncol Biol Phys. 1999;45:1055–1062
  104. Svensson JP, Stalpers LJA, Lange REEE, et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med. 2006;3:e422
  105. Hümmerich J, Werle-Schneider G, Popanda O, et al. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance. A pilot study in prostate cancer patients receiving radiotherapy. Int J Radiat Biol. 2006;82:593–604
  106. Cesaretti JA, Stock RG, Atencio DP, et al. A genetically determined dose–volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;68:1410–1416
  107. Peters CA, Stock RG, Cesaretti JA, et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:752–759
  108. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006;12:2545–2554
  109. Burri RJ, Stock RG, Cesaretti JA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res. 2008;170:49–59
  110. Valdagni R, Rancati T, Ghilotti M, et al. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose–volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2009;74:1431–1440
  111. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  112. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1257–1280
  113. Cheung MR, Tucker SL, Dong L, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1059–1065
  114. Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose–volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100–1109
  115. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337
  116. Lips IM, Denhad H, van Glis CH, et al. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol. 2008;3:15
  117. Al Mangaani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of Intensity-modulated Radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685–691
  118. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  119. Heemsbergen W, Witte M, Al-Mamgani A, et al. GU toxicity after RT for prostate cancer: dose maps and dose surface data to identify dose–effect relationships. Radiother Oncol. 2008;88:S83–S84
  120. Liu M, Pickles T, Agranovich A, et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2004;58:59–67
  121. Letschert JG, Lebesque JV, Aleman BM. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol. 1994;32:116–123
  122. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol. 1995;13:1409–1416
  123. Baglan KL, Frazier RC, Yan D, et al. The dose–volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:176–183
  124. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;69:201–207
  125. Sanguineti G, Endres EJ, Sormani MP, Parker BC. Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. Strahlenther Onkol. 2009;185:390–396
  126. Huang EY, Sung CC, Ko SF, et al. The different volume effects of small-bowel toxicity during pelvic irradiation between gynaecological patients with and without abdominal surgery: a prospective study with computed-tomography-based dosimetry. Int J Radiat Oncol Biol Phys. 2007;69:732–739
  127. Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose–volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys. 2006;66:505–513
  128. Robertson JM, Lockman D, Yan D, Wallace M. The dose–volume relationships of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:413–418
  129. Fiorino C, Alongi F, Perna L, et al. Dose–volume relationship for acute bowel toxicity for patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75:29–35
  130. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995;13:1303–1311
  131. van Duijvendijk P, Slors F, Taat CW, et al. A prospective evaluation of anorectal function after total mesorectal excision in patients with a rectal carcinoma. Surgery. 2003;133:56–65
  132. Vargas C, Yan D, Kestin LL, et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose–volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys. 2005;63:141–149
  133. Muren LP, Smaaland R, Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol. 2003;69:291–304
  134. Kvinnsland Y, Muren LP. The impact of organ motion on intestine doses and complication probabilities in radiotherapy of bladder cancer. Radiother Oncol. 2005;76:43–47
  135. Hysing LB, Kvinnsland Y, Lord H, et al. Planning organ at risk volume margins for organ motion of the intestine. Radiother Oncol. 2006;80:349–354
  136. Sanguineti G, Little M, Endres EJ, et al. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiother Oncol. 2008;88:95–101
  137. Fokdal L, Honore H, Hoyer M, et al. Dose–volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol. 2005;74:203–210
  138. Letschert JG. The prevention of radiation-induced small bowel complications. Eur J Cancer. 1995;31A:1361–1365
  139. Hysing LB, Skorpen TN, Alber M, et al. Influence of organ motion of conformal vs intensity-modulated pelvic radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:1496–1503
  140. Fisch BM, Pickett B, Weinberg V, et al. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology. 2001;57:955–959
  141. Pickett B, Fisch BM, Weinberg V, et al. Dose to the bulb of the penis is associated with the risk of impotence following radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:263
  142. Merrick GS, Butler WM, Wallner KE, et al. The importance of radiation doses to the penile bulb vs. Crura in the development of post brachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys. 2002;54:1055–1062
  143. Mangar SA, Sydes MR, Tucker HL, et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer. Radiother Oncol. 2006;80:355–362
  144. Wernicke AG, Valicenti R, DiEva K, et al. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1357–1363
  145. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;60:1351–1356
  146. Incrocci L, Slob AK, Levenday PC. Sexual (dys) function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys. 2002;52:681–693
  147. Kitelet RA, Lee WR, deGuzman AF, et al. Radiation dose to neurovascula bundles of penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy. 2002;1:90–94
  148. Selek U, Cheng R, Lii M, et al. Erectile dysfunction and radiation dose to the penile base structures: a lack of correlation. Int J Radiat Oncol Biol Phys. 2004;59:1039–1046
  149. Algan O, Hanks GE, Shaer AH. Localization of the prostatic apex for radiation treatment planning. Int J Radiat Oncol Biol Phys. 1995;33:925–930
  150. Sethi A, Mohideen N, Leybovich L, Mulhall J. Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;55:970–978
  151. McLaughlin P, Narayana V, Meirovitz A, et al. Vessel-sparing prostate radiotherapy dose limitation to critical erectile vascular structures (internal pudental artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys. 2005;61:20–31
  152. Perna L, Fiorino C, Cozzarini C, et al. Sparing the penile bulb in the radical irradiation of clinically localized prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and helical tomotherapy. Radiother Oncol. 2009;93:57–63
  153. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;40:129–133
  154. Mulhall JP, Yonover PM. Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy for prostate cancer. Urology. 2001;58:828
  155. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582–1592
  156. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–463
  157. Goldstein I, Feldman MI, Deckers PJ, et al. Radiation-associated impotence. A clinical study of its mechanism. JAMA. 1984;251:903–910
  158. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:1063–1068
  159. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830
  160. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998;159:1988–1992
  161. O’Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry. 1984;145:146–151
  162. Saad F, Grahl AS, Aversa A, et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int. 2007;99:988–992
  163. Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf). 2000;53:517–522
  164. Yoon FH, Perera F, Fisher B, et al. Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. Int J Radiat Oncol Biol Phys. 2009;74:1186–1190
  165. Pickles T, Agranovich A, Berthelet E, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer. 2002;94:362–367
  166. Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008;180:1432–1437discussion 1437
  167. Pickles T, Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter?. J Urol. 2002;167:2448–2452
  168. Wilke DR, Parker C, Andonowski A, et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone–releasing hormone agonists. BJU Int. 2006;97:963–968
  169. Teloken PE, Ohebshalom M, Mohideen N, et al. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol. 2007;178:2521–2525
  170. Incrocci L, Koper PC, Hop WC, et al. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys. 2001;51:1190–1195
  171. Daniell HW, Clark JC, Pereira SE, et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer. 2001;91:1889–1895
  172. Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;39:85–89
  173. Boehmer D, Badakhshi H, Kuschke W, Bohsung J, Budach V. Testicular dose in prostate cancer radiotherapy: impact on impairment of fertility and hormonal function. Strahlenther Onkol. 2005;181:179–184
  174. Herrmann T. Radiation reactions in the gonads: importance in patient counselling. Strahlenther Onkol. 1997;173:493–501
  175. Yau I, Vuong T, Garant A, et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:1481–1486
  176. Izard MA. Leydig cell function and radiation: a review of the literature. Radiother Oncol. 1995;34:1–8
  177. Piroth MD, Hensley F, Wannenmacher M, Zierhut D. Male gonadal dose in adjuvant 3-D-pelvic irradiation after anterior resection of rectal cancer. Influence to fertility. Strahlenther Onkol. 2003;179:754–759
  178. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73:1304–1312
  179. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62:738–744
  180. Bedford JL, Khoo VS, Webb S, Dearnaley DP. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 2000;46:231–238
  181. Herman MP, Kopetz S, Bhosale PR, et al. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009;74:818–823
  182. Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005;294:2587–2593
  183. Small W, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research?. JAMA. 2005;294:2635–2637
  184. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26:5465–5476
  185. Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356–1365
  186. Sacks EL, Goris ML, Glatstein E, et al. Bone marrow regeneration following large field radiation: influence of volume, age, dose and time. Cancer. 1978;42:1057–1065
  187. Rubin P, Landman S, Mayer E, et al. Bone marrow regeneration and extension after extended field irradiation in Hodgking’s disease. Cancer. 1973;32:699–711
  188. Brixey CJ, Roeske JC, Lujan AE, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynaecologic cancer. Int J Radiat Oncol Biol Phys. 2002;54:1388–1396
  189. Lujan AE, Mundt AJ, Yamada SD, et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:516–521
  190. Ahmed RS, Kim RY, Duan J, et al. IMRT dose escalation for positive paraortic lymphnodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys. 2004;60:505–512
  191. Roeske JC, Lujan AE, Reba RC, et al. Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynaecologic malignancies. Radiother Oncol. 2005;77:11–17
  192. Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1431–1437
  193. Mutyala S, Thawani N, Vainsthein JM, et al. Dose constraints recommendations and a predictive nomogram of incidence of hematological toxicity for cervix cancer patients treated with concurrent cisplatin and intensity modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys. 2008;72:S359–S360
  194. Shasha D, Homel P, Wagner JR, et al. Predictors of anemia in patients treated with radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:S298–S299
  195. Choo R, Chander S, Danjoux C, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate patients?. Can J Urol. 2005;12:2547–2552
  196. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1989;16:1173–1178
  197. Pai HH, Ludgate C, Pickles T, Paltiel C, et al. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:990–998
  198. Valdagni R, Rancati T, Fiorino C, et al. Development of nomograms to predict moderate/severe late rectal bleeding in prostate cancer patients undergoing 3DCRT. Radiother Oncol. 2008;88:S150
  199. Valdagni R, Rancati T, Fiorino C. Predictive models of toxicity in external radiotherapy for prostate cancer: clinical issues. Cancer. 2009;115:3141–3149

PII: S0167-8140(09)00437-X

doi: 10.1016/j.radonc.2009.08.004

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 153-167 , November 2009

Article Tools

* Image Usage & Resolution